OncoQR

Two entrepreneurial scientists with business experience have created a technology platform for immunology vaccines that make cancer and allergy treatment possible. For product development and technology commercialisation, they founded two startups, S-TARget therapeutics and OncoQR. Thanks to a robust patent portfolio and an IP strategy supporting their business case, they followed several commercialisation pathways, including investments in own research and development, collaborative development and technology out-licensing. IP was essential for gaining revenues early on through licensing as well as for attracting funding. This was crucial given the long time-to-market periods that are typical in biotechnology.